Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

12P - The correlation between non-coding RNA and response rate to immune-checkpoint inhibitors


09 Dec 2020


e-Poster Display Session


Dmitrii Shek


Annals of Oncology (2020) 31 (suppl_7): S1417-S1424. 10.1016/annonc/annonc389


D. Shek1, S. Read2, A. Nagrial3, M. Carlino4, J. George5

Author affiliations

  • 1 Western Sydney University - School of Medicine, 2148 - Campbelltown/AU
  • 2 Westmead Institute for Medical Research, Blacktown/AU
  • 3 Westmead Hospital, Blacktown/AU
  • 4 Melanoma Institute Australia, Wollstonecraft/AU
  • 5 The University of Sydney, Westmead/AU

Abstract 12P


Immune-checkpoint inhibitors (ICIs) have revolutionized clinical oncology in recent years. ICIs are monoclonal antibodies (mAbs) that block inhibitory CTLA-4 and PD-1 signalling pathways and boost cytotoxic T cell antitumor activity. Currently, there is a lack of knowledge regarding factors associated with ICI efficacy and safety. Non-coding RNAs (ncRNAs) are abundant (up to 70% of the human genome) regulators of gene expression, with proven abilities to promote cancer drug resistance. This study aims to determine an association between tumour ncRNA and response to ICI therapy.


Gene expression data was downloaded from the NCBI GEO database. Effect-size (standardized mean difference [SMD]) was calculated using Hedges’ g method and further meta-analysis was conducted in Stata v16 software. DAVID online bioinformatics tool was used to determine proteins and pathways associated with abnormally expressed ncRNAs.


We identified two datasets derived from patients undergoing anti-PD-1 mAb (nivolumab) therapy: GSE79691 (metastatic melanoma [MM]) and GSE67501 (renal cell carcinoma [RCC]). Both studies evaluated RNA from formalin-fixed paraffin embedded (FFPE) specimens. MiR-27B (p=0.02) and miR-let7D (p=0.003) were significantly higher among non-responders to ICI therapy compared to responders in both datasets. In particular, SMD was 4.57 (miR-27B) and 3.9 (miR-let7D) higher among non-responders in both studies with low study heterogeneity scores (I2=22.67% and T2=0.36). In comparison, analysis of datasets GSE99898 (MM) and GSE74174 (RCC) using kinase inhibitors found no significant association between treatment response and the aforementioned microRNAs. Because miR-27B and miR-let7D influence PI3K/Akt and Wnt/β-catenin signalling pathways, further studies are required to validate whether these microRNAs modulate cancer progression in general or are unique to ICI therapy response.


We have established that miR-27B and miR-let7D are increased among non-responders to ICI therapy supporting their possible predictive role for ICI therapeutic response.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.